This week: the plateau piece we have been promising, because “just be patient” is not much of an explanation, and a muscle-preservation claim that finally gets its grade.

Let's go. ☕

Your GLP-1 stalled. You restarted and it's not working. What the science actually says.

There are three versions of this question everywhere right now. The scale stopped. Why? I stopped, regained, restarted, and round two feels completely different. Or: this medication never really worked that well for me. Is that actually possible?

Yes. All three are real questions. And the trials give us more useful answers than “be patient.”

A plateau is what the trials predicted, not a malfunction

Weight loss on these medications was never a straight line down. It happens faster early on, slows over time, and eventually levels off on average. With semaglutide, the two-year STEP 5 trial showed average weight loss beginning to plateau around week 60, then staying relatively stable through week 104. Tirzepatide followed a somewhat different curve. In a later analysis of the SURMOUNT trials, the median time to a defined weight plateau ranged from about 24 to 36 weeks, depending partly on starting BMI, and close to 9 in 10 participants had reached a plateau by week 72.

So there is no magic week when a GLP-1 suddenly “stops working.” And a plateau does not automatically mean the medication failed. As you lose weight, you are carrying a smaller body. Your energy needs drop. At the same time, appetite and other biological signals involved in weight regulation can start pushing back against further loss. That response is well documented with weight loss.

So instead of asking “why did my medication stop working?” a better question may be: “is this where my current treatment has brought me, and what does that mean for the next step?” That is a much more useful conversation to have with a prescriber than trying to force the scale on your own.

Stopping and regaining is physiology, not failure

The withdrawal data are pretty hard to ignore. In the STEP 1 extension, people who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost over the following year. The structured lifestyle intervention ended at the same time, so the study cannot tell us what would have happened if intensive lifestyle support had continued.

Tirzepatide tells a similar story. In SURMOUNT-4, everyone first received tirzepatide for 36 weeks. Some continued treatment. Others were switched to placebo, while lifestyle counseling continued in both groups. Over the following year, the group switched off tirzepatide regained an average of about 14% of their body weight from the point they stopped, while the group that stayed on treatment lost another 5.5%.

Different trial. Same overall message. For many people, a large part of the weight-management effect does not continue once treatment is withdrawn. That does not mean everyone who stops will regain everything. It does mean regain is a documented biological pattern, not evidence that someone suddenly lost all discipline. Stopping is not “graduation.” It is another treatment decision.

The second-round question

This one comes up constantly: “why did it work so well the first time, but barely seems to move the scale now that I restarted?” The most accurate answer right now is: we do not really know yet.

People absolutely stop and restart these medications. A 2026 real-world study of nearly 8,000 people who discontinued semaglutide or tirzepatide found that about 1 in 5 restarted the original medication within the next year. But the study did not tell us whether round two worked better, worse or exactly the same. And we could not find good controlled human evidence showing that taking a break permanently creates GLP-1 “resistance” or makes tirzepatide or semaglutide less effective the second time around.

There is another reason round one and round two may not be an apples-to-apples comparison. After a long interruption, the restart plan may not put you immediately back where you left off. For Zepbound, the current FDA label tells you what to do after a single missed dose, but it does not give one standard restart schedule for someone who has been off treatment for six months. Some clinical trial protocols restarted tirzepatide at a lower dose after longer interruptions, but that is specific to those protocols, not a universal rule.

So yes, a slower restart can be frustrating. But “my body is resistant now” is not something the evidence can confirm. At least not yet.

Lower responders are real, and nobody puts them in the ad

Not everyone has a dramatic response. In STEP 1, 86.4% of people taking semaglutide lost at least 5% of their body weight by week 68. Flip that around and about 13.6%, roughly 1 in 7, did not reach 5%. Tirzepatide also showed a range of responses. In SURMOUNT-1, 85%, 89% and 91% of participants reached at least 5% weight loss on the three studied doses. That means roughly 9% to 15% did not, depending on the treatment group.

We would not automatically call everyone below 5% a “non-responder.” Five percent is a useful clinical benchmark. It is not a biological test that tells us someone is resistant to the medication. But the bigger point is important: response varies. Some people lose 25%. Some lose 5%. Some lose less. That variability was already in the trials. Social media just does not show you that part as often.

If months of treatment have produced much less change than expected, the answer is not to quietly push harder on your own. That is exactly when the prescriber conversation matters most.

What to do with this

• Look at the overall trajectory, not one week on the scale. Depending on your situation, waist measurements, symptoms, strength, relevant labs or body composition may add useful context.
• Ask your prescriber what a reasonable treatment curve looks like for your medication and your situation, not somebody else's month-three TikTok.
• If you are thinking about stopping, include the withdrawal and regain data in that conversation.
• If you stopped, regained and restarted, do not diagnose yourself with “resistance” just because the second experience feels slower.
• And do not change your own dose trying to force a plateau to move.

That second number needs some context, because the research is starting to catch up. A post hoc SURMOUNT analysis later grouped women by reproductive stage and found substantial tirzepatide-associated weight loss across premenopause, perimenopause and postmenopause. But reproductive stage had to be assigned retrospectively, because the original trials were not designed around it. A 2026 analysis using STEP 1 and SELECT data also found signals suggesting menopausal hormonal status may affect semaglutide-associated weight loss in women. But again, this was exploratory, not a menopause-specific randomized trial.

So the question is finally being asked. It just was not built into the original trials. Women asking “why did mine stall?” deserve better than being told hormones and life stage do not matter. They also deserve better than being told we already know exactly how much they matter. We do not.

“With the right supplements and peptides, you can keep all your muscle on a GLP-1.”

What the evidence says. The concern underneath the marketing is real. When people lose a significant amount of weight, some lean mass usually comes with it. A 2026 meta-analysis of 20 randomized trials found that lean mass accounted for roughly 25% to 39% of total weight lost with incretin-based medications, depending on the medication and study. The estimate was about 35% with semaglutide and 25% with tirzepatide.

That sounds scary until you add some context. First, lean mass is not the same thing as muscle. DXA-defined lean mass includes water, organs and other non-fat tissue along with skeletal muscle. Second, lean-mass loss is not unique to GLP-1 treatment. In the same meta-analysis, lifestyle-based weight-loss interventions produced a broadly similar proportion of lean-mass loss. Resistance training improved the picture.

The individual drug studies tell a similar story. In the SURMOUNT-1 DXA substudy, about 74% of the weight lost with tirzepatide was fat mass and 26% was lean mass. In the STEP 1 body-composition substudy, semaglutide reduced total fat mass by 19.3%, visceral fat by 27.4% and lean body mass by 9.7%. Lean mass went down in absolute terms, but because fat fell more, lean mass actually made up a slightly larger share of total body weight by the end.

So yes, muscle preservation matters. No, your GLP-1 is not simply “eating your muscle.”

What actually has evidence. The least exciting answer wins again: enough protein and resistance training. Current obesity-care guidance emphasizes adequate protein intake and resistance exercise during weight loss to help preserve lean mass and function. A multidisciplinary GLP-1 nutrition advisory says essentially the same thing and makes another important point: protein alone is unlikely to be enough without strength training. That does not mean everyone needs the same protein target or the same workout plan. And research specifically testing muscle-preservation strategies alongside the newest high-potency medications is still developing. But the basics are not mysterious.

What we could not find was controlled human evidence showing that a marketed supplement or so-called “muscle-sparing peptide” can fully prevent lean-mass loss during semaglutide or tirzepatide treatment. A protein powder can absolutely be useful if it helps someone meet their nutrition needs. That is not the same as proving it prevents muscle loss. And an unapproved peptide does not become evidence-based because somebody puts “recovery” or “muscle preservation” on the label. The pitch takes a real concern, adds a guarantee the evidence cannot support, and sends the anxiety straight toward the checkout button.

The fair version of the claim: you probably do have some influence over how much lean tissue you preserve during weight loss. The tools with the strongest support are adequate nutrition, enough protein and progressive resistance exercise. A protein shake can make meeting protein needs easier. Resistance training gives the muscle a reason to stay. But nobody has earned the promise: “you can keep all your muscle.”

Worth your inbox

Researching health for yourself is one job. Doing it for an aging parent at the same time is two. GrayBrief is a plain-English education resource for adult children navigating elder care: what to ask, what to watch for, and what nobody tells you until it's urgent. If that's your season of life, it's worth a look.

I would not call it resistance based on what we know today. People do report that restarting feels different, but we do not have good human evidence showing that taking a break from tirzepatide permanently makes your body less responsive to it.

The truth is, we know much more about what happens after stopping than what happens after restarting. The withdrawal trials clearly show that regain is common. What we do not have is a good study comparing the first course of treatment with the second course after a long break.

And a restart may not be a direct continuation of where you left off. The current Zepbound label tells you what to do after a single missed dose, but it does not give one standard restart plan after being off the medication for six months. That decision depends on the situation and belongs with your prescriber.

So instead of deciding that your body has become resistant, I would bring the actual timeline to the appointment: what dose were you on before you stopped? What is the restart plan now? How long have you been back on treatment? What has happened to your weight, appetite and other symptoms since restarting? That gives your prescriber something much more useful to work with.

The slower response may be real. The frustration is real. But the resistance theory is not proven. And I would not change the dose on your own trying to fix something we do not fully understand yet.

Mais, PharmD, Medical Reviewer, Pep in Her Step

• GLP-1 side effects: the ones that are annoying, the ones that are emergencies, and how to tell the difference.
• Rash to radiance: the strange two-sided skin story GLP-1 users keep reporting.
• Pill versus pen: what the oral semaglutide data actually shows.